Recent developments include the completion of a merger with Viskase Companies, a reverse stock split, and changes in board composition. Historical news highlights the company’s royalty-based business model and shareholder activities.

• Enzon Pharmaceuticals completed a merger with Viskase Companies on March 26, 2026, resulting in Viskase becoming a wholly owned subsidiary and the company changing its name to Viskase Holdings, Inc. [S1]
• The company executed a 1-for-100 reverse stock split on March 24, 2026, affecting its common stock trading on the OTCQB market [S1]
• Post-merger, several directors resigned and new directors were appointed to the board, reshaping governance [S1]
• The company’s business model historically involved generating royalties and cash flows, as discussed in 2019 Nasdaq articles [N1][N2]
• Carl Icahn and affiliates have been significant shareholders, including involvement in exchange offers for Series C Preferred Stock [N3]
• The company has a history of dividend payments with scheduled ex-dividend dates in prior years [N4][N5]

The company’s substantial cash reserves and strong liquidity ratios as of December 31, 2025, provide financial flexibility. The merger with Viskase Companies could create operational synergies and broaden the business scope. The historical royalty-based business model offers a steady cash flow component. Experienced board members and management with backgrounds in finance and governance may support effective strategic execution. The reverse stock split and restructuring may improve market perception and trading liquidity on the OTCQB market.

The company reported minimal revenue and a net loss for the fiscal year ending December 31, 2025, indicating limited operational profitability. The delisting from Nasdaq and trading on OTCQB may reduce visibility and investor interest. The merger and corporate restructuring introduce integration risks and potential disruptions. The historical reliance on royalties may limit growth opportunities. Changes in shareholder composition and board resignations could impact governance continuity. The company’s small scale and financial losses present challenges to long-term sustainability without clear operational expansion.

Enzon Pharmaceuticals’ moat historically derived from its royalty streams and cash flow generation from intellectual property and licensing agreements. The company’s business model focused on monetizing royalties rather than active pharmaceutical development or commercialization. The involvement of significant shareholders such as Carl Icahn and the company’s governance structure with experienced directors and management provided oversight and strategic direction. However, the company’s minimal revenue and net losses indicate limited operational scale. The recent merger with Viskase Companies and subsequent corporate restructuring may alter the company’s moat dynamics going forward.

• Merger Integration Risk: The recent merger with Viskase Companies involves integration challenges that could disrupt operations and affect financial performance.
• Limited Revenue and Profitability: Minimal revenue and net losses reported indicate challenges in achieving sustainable profitability.
• Market Listing and Liquidity Risk: Delisting from Nasdaq and trading on OTCQB may reduce market visibility and liquidity, impacting investor access.
• Dependence on Royalty Streams: The historical business model’s reliance on royalties may limit growth and expose the company to risks if royalty streams decline.
• Governance and Management Changes: Resignations and board changes post-merger may affect governance stability and strategic continuity.

• Enzon Pharmaceuticals, Inc. completed a merger with Viskase Companies, Inc. on March 26, 2026, after which it changed its name to Viskase Holdings, Inc. [S1]
• The merger involved Viskase Companies becoming a wholly owned subsidiary of Enzon and converting into a Delaware limited liability company [S1]
• Enzon effected a 1-for-100 reverse stock split on March 24, 2026 [S1]
• Post-merger, the board composition changed with several directors resigning and new directors appointed, including Dustin DeMaria, Robert E. Flint, Colin Kwak, Kenneth Shea, and Peter K. Shea [S1]
• The company’s common stock is no longer listed on Nasdaq and trades on the OTCQB market [S1]
• The company had cash and cash equivalents of $42.57 million as of December 31, 2025 [S1]
• Current assets were $42.81 million and current liabilities were $0.73 million as of December 31, 2025, resulting in a current ratio of 58.57 and a cash ratio of 92.78 [S1]
• Revenue reported for the fiscal year ending December 31, 2025 was $26,000, with a net loss of $3.41 million and basic and diluted EPS of -$0.07 [S1]
• The company’s business model historically involved royalties and cash flows, as discussed in 2019 Nasdaq articles [N1][N2]
• Carl Icahn and affiliates have been involved as significant shareholders, including exchange offers for Series C Preferred Stock [N3]
• The company has a history of paying dividends, with ex-dividend dates scheduled in prior years [N4][N5]
• The company’s board and management team have extensive experience in finance, governance, and related industries [S1]
• The company’s financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice [S1]